A Pivotal, Comparative Pharmacokinetic Study Characterizing the Systemic Exposure, Pharmacokinetics, Apparent Dose, Bioequivalence, and Safety of the Investigational Lidocaine Patch (ZTlido) Against Lidoderm in Healthy Subjects

Trial Profile

A Pivotal, Comparative Pharmacokinetic Study Characterizing the Systemic Exposure, Pharmacokinetics, Apparent Dose, Bioequivalence, and Safety of the Investigational Lidocaine Patch (ZTlido) Against Lidoderm in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Postherpetic neuralgia
  • Focus Pharmacokinetics; Registrational
  • Sponsors Scilex Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2018 According to a Sorrento Therapeutics media release, the U.S. Food and Drug Administration (FDA) has approved ZTlid (lidocaine topical system) 1.8% for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain.
    • 12 Sep 2017 According to a Sorrento Therapeutics media release, SCILEX Pharmaceuticals Inc. a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration (FDA) acknowledgement of receipt of its recently resubmitted New Drug Application (NDA) for ZTlido(lidocaine patch 1.8%) which has been considered a complete, class 2 response to the prior action letter. The PDUFA date is set for February 28, 2018 .
    • 29 Aug 2017 According to a Sorrento Therapeutics media release, data from this trial was used to resubmit the NDA and all FDA comments related to the initial NDA submission for the lead product candidate, ZTlido (lidocaine patch 1.8%) were responded by SCILEX Pharmaceuticals Inc.(a majority-owned subsidiary of Sorrento).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top